SillaJen
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
O2 Tower 83 Uisadang-daero 11TH Fl, Yeon...Phone Number
(415) 281-8886Website
www.sillajen.comRevenue
<$5 MillionStock Symbol
215600Industry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About SillaJen
Founded in 2003 and headquartered in South Korea, SillaJen is a biotechnology company that is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVE platform.Explore more
SillaJen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SillaJen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if SillaJen has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at SillaJen
Earning: See what the market has to say on SillaJen recently announced quarterly report
Funding: Get notified immidiatlly once SillaJen has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if SillaJen is spiking on competitors!
Product Launch: Get notified when SillaJen launches new products
Click to see if SillaJen had a recent Job posting/layoffs
SillaJen, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined SillaJen as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
SillaJen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SillaJen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SillaJen.
SillaJen Tech Stack
SillaJen News & Media
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
SEOUL, South Korea--(BUSINESS WIRE)-- #BAL0891--SillaJen has submitted CSR to US FDA for REN026. This is a phase 1b/2a dose escalation study designed to evaluate the safety and efficacy of REN026.M2N to sell 52% stake in Chinese automotive parts company DKCA - KED Global
M2N(DK D&I Co.), the parent company of pharmaceutical firm Sillajen Inc., announced on Tuesday that it has signed an agreement to sell its majority stakeBasilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance
Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approximately USD 320 million and tiered royalties on net salesSecond oncology transaction as part of strategic refocusing on anti-infectivesFull-year 2022 revenue guidance increased, resulting in improved expected operating result and operating cash flow Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, September 20, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage bOncolytic Virus Therapy Market is Expected to Generate Huge Profits By 2028 | Lokon Pharma AB, Targovax, SillaJen, etc
Oncolytic Virus Therapy Market Growth – at a CAGR of 23.9%, Market Trends – Increased investments in research and development of advanced cancer therapies. VANCOUVER, BC, CANADA, May 4, 2022 /EINPresswire.com/ -- Increasing prevalence of cancer and …
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SillaJen
Sign Up For FreeTo access detailed company insights
Founded in 2003 and headquartered in South Korea, SillaJen is a biotechnology company that is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVE platform.... Read More
